DEA Revokes Utah Nurse Practitioner’s Controlled-Substance Registration
Published Date: 11/12/2026
Notice
Summary
Traci B. Lujan, a nurse practitioner from Utah, lost her DEA registration because she no longer has permission to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her certificate. This means she can’t legally prescribe or manage certain medications anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for APRN
The DEA revoked Certificate of Registration No. ML5284815 issued to Traci B. Lujan, A.P.R.N. because Utah revoked her RN, APRN, and APRN controlled substance licenses effective April 21, 2026. The DEA order revoking her registration is effective December 14, 2026, and she is therefore not authorized by DEA to prescribe, dispense, or otherwise handle controlled substances after that date.
Pending DEA Applications Denied
The DEA denied any pending applications by Traci B. Lujan to renew or modify Certificate No. ML5284815 and denied any other pending application for additional registration in Utah. That denial is part of the same Order effective December 14, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22955, Troy R. Lehman, D.O.; Decision and Order
Troy R. Lehman, D.O., lost his DEA registration because he didn’t have the proper state permission and lied on his renewal forms. Since he didn’t ask for a hearing, the DEA revoked his registration by default, stopping him from handling controlled substances. This change is effective immediately and means he can no longer legally work with these drugs.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
Previous / Next Documents
Previous: 2026-22950, Wood Mouldings and Millwork Products From the People's Republic of China: Final Results of Countervailing Duty Administrative Review; 2024
The U.S. Department of Commerce found that Chinese companies making wood mouldings and millwork products got unfair government help during 2024. Because of this, extra duties will apply starting November 12, 2026, affecting importers and sellers of these products. This means prices might change, and businesses should get ready for the new rules.
Next: 2026-22955, Troy R. Lehman, D.O.; Decision and Order
Troy R. Lehman, D.O., lost his DEA registration because he didn’t have the proper state permission and lied on his renewal forms. Since he didn’t ask for a hearing, the DEA revoked his registration by default, stopping him from handling controlled substances. This change is effective immediately and means he can no longer legally work with these drugs.